Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.69 and traded as high as $0.8723. Brainstorm Cell Therapeutics shares last traded at $0.8645, with a volume of 6,947 shares.
Brainstorm Cell Therapeutics Stock Up 1.7%
The stock’s fifty day simple moving average is $0.76 and its two-hundred day simple moving average is $0.69. The firm has a market cap of $9.54 million, a PE ratio of -0.26 and a beta of 0.30.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Recommended Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
